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Abstract
Background: The tolerability and efficacy of single dose albendazole (400 mg), diethylcarbamazine
citrate (DEC) (6 mg/kg bodyweight) or co-administration of albendazole (400 mg) + DEC (6 mg/kg
bodyweight) was studied in 54 asymptomatic Wuchereria bancrofti microfilaraemic volunteers in a
double blind hospital-based clinical study.
Results: There was no significant difference in the overall incidence of adverse reactions between
the three drug groups [42.1% (albendazole), 52.9% (DEC) and 61.1% (albendazole + DEC); P >
0.05]. The mean score of adverse reaction intensity did not differ significantly between the DEC
and albendazole + DEC groups. However, the values in these two groups were significantly higher
compared to that of albendazole alone [1.8 ± 3.0 (albendazole) vs. 5.6 ± 7.1 (DEC), 6.7 ± 6.6
(albendazole + DEC); P < 0.05]. By day 360 post-therapy there was no significant difference
between the three drug groups in relation to the clearance of microfilaria [26.3% (albendazole),
17.6% (DEC), 27.8% (albendazole + DEC)], reduction in geometric mean parasite density [94.7%
(albendazole), 89.5% (DEC), 95.4% (albendazole + DEC)] or reduction in filarial antigenaemia [83%
(albendazole), 87% (DEC), 75% (albendazole + DEC)]. Furthermore, there was a significant
decrease in mean geometric parasite density (P < 0.05) as well as antigenaemia optical density
values (P < 0.01) between pre-therapy levels and day 360 post-therapy in all three groups.
Conclusions: This study has shown that single dose albendazole (400 mg) has similar efficacy in
the clearance of microfilaria as that of DEC or the co-administration of the two drugs. The results
strengthen the rationale of using albendazole for mass annual single dose administration for the
control of transmission of lymphatic filariasis.
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Background
Lymphatic filariasis is endemic in as many as 80 countries
and has been targeted for global elimination as a public
health problem. Recently, the control and elimination
programmes for this disease have undergone a paradigm
shift from mass detection and selective treatment to re-
peated annual mass drug administration (MDA) in en-
demic communities and implementation units.
Furthermore, the strategy of MDA has moved from a sin-
gle dose regime of diethylcarbamazine citrate (DEC) to
co-administration of albendazole with DEC in areas
where onchocerciasis is not co-endemic [1].
In India, a total of 553 million people live in areas endem-
ic for lymphatic filariasis and there are approximately 21
million people with symptomatic filariasis and 27 million
who have asymptomatic microfilaraemia [2,3]. Apart
from the National Filariasis Control Programme (NFCP),
which currently covers about 40 million people at risk, pi-
lot projects using single annual MDA with DEC alone or
in combination with albendazole have been running
since 1996 and currently cover about 50 million people at
risk in different regions of India [4–6].
Although the tolerability and efficacy of single dose DEC
or ivermectin has been established in both a hospital-
based study [8] and community-based MDA [3,4,6,7] for
the treatment of bancroftian filariasis in India, no similar
published data exists for either single dose albendazole,
alone or in combination with DEC. For this reason, the
present study was undertaken which examined the tolera-
bility and efficacy of a single dose of albendazole (400
mg) compared with DEC (6 mg/kg bodyweight) or co-ad-
ministration of albendazole (400 mg) + DEC (6 mg/kg
bodyweight).
Table 1: Inclusion/exclusion criteria used for recruitment of patients in the study
Inclusion criteria Exclusion criteria
a) Apparently healthy individuals with normal body weight for age a) Haemoglobin < 10 gm/dl or Haematocrit < 30%
b) W. bancrofti microfilaraemia (in one millilitre of venous blood collected 
between 8.30 and 9.30 p.m.)
b) Symptoms/signs of any chronic illness
c) Normal electro-cardiogram (ECG) c) Patients with a history of any drug intolerance, reaction or 
allergy
d) Normal chest X-ray d) Presence of cysts or ova of intestinal helminths by routine 
stool examination
e) Results within normal limits in routine stool and urine examination e) Patients giving history of consuming either albendazole or 
DEC in the preceding year
f) Results within normal limits for haemoglobin concentration, total white 
blood cell count, differential count, absolute eosinophil count, erythrocyte 
sedimentation rate, packed cell volume
f) Declared unfit by physician for any other reason.
g) Results within normal limits for blood urea, glucose, bilirubin, creatinine, 
cholesterol; serum sodium, potassium, chloride, protein, albumin, globulin, 
serum glutamic pyruvic transaminase, alkaline phosphatase
Table 2: Drug regimen and mean pre-therapy Wuchereria bancrofti microfilaraemia levels in the three single dose drug groups
Group No. patients ≤  14 yearsa No. patients >14 yearsa Total No. of patients Drug regimenb Pre-therapy microfilaraemia 
(per mL)c
1 5 m, 4 f 5 m, 5 f 19 Alb 400 mg 77.6 (22 – 606)
2 3 m, 4 f 5 m, 5 f 17 DEC 6 mg/kg body-
weight
81.3 (22 – 542)
3 4 m, 4 f 5 m, 5 f 18 Alb 400 mg + DEC 6 
mg/kg bodyweight
79.4 (24 – 223)
a m = male, f = femaleb Alb = albendazole, DEC = diethylcarbamazine citrate c Geometric mean (range in parentheses): the pre-therapy values 
between the 3 drug groups did not differ significantly (F = 0.024, P = 0.976).Filaria Journal 2002, 1 http://www.filariajournal.com/content/1/1/1
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Materials and Methods
Fifty four 'healthy' asymptomatic microfilaraemic volun-
teers between the ages of 10 and 57 years (mean = 24.67),
who had previously been selected by use of an inclusion/
exclusion criteria (Table 1), and who had given written in-
formed consent (see note), were admitted to the Govern-
ment General Hospital at Pondicherry for a period of five
days and randomly allocated into one of three single dose
drug groups (Table 2).
On day 0, baseline clinical examination and laboratory
investigations including night blood examination for mi-
crofilaria (mf) were carried out. The following morning,
(Day 1), the appropriate drug regimen was administered
to the patients on an empty stomach under the direct su-
pervision of the medical team. All patients were clinically
monitored for adverse reactions (such as fever, headache,
myalgia, chill, abdominal pain, arthralgia, cough, diar-
rhoea, dizziness, nausea, vomiting and chest pain), at 8
hourly intervals for a period of 24 hours, and thereafter
every 24 hours for a further 3 days. All systemic adverse re-
actions were recorded by assigning them a score of either
0 (none) or 1 (mild) or 2 (moderate) or 3 (severe).
Laboratory tests (haemoglobin concentration, total white
blood count, differential count, absolute eosinophil
count, erythrocyte sedimentation rate, packed cell vol-
ume, blood urea, glucose, bilirubin, creatinine, cholester-
ol, serum sodium, potassium, chloride, protein, albumin,
globulin, serum glutamic pyruvic transaminase, alkaline
phosphatase) were carried out on days 0 and 7. A routine
stool and urine analysis was included with the laboratory
tests. Blood samples were collected on days 0, 3, 7, 30, 90,
180, 270 and 360, the serum separated and stored at -
20°C until assay for circulating filarial antigen. Microfilar-
ia counts were also performed on days 0, 3, 7, 30, 90, 180,
270 and 360.
The study conformed to the principles of Helsinki Decla-
ration II [9], the Guidelines for Good Clinical Practice
(GCP) for Trials on Pharmaceutical Products [10] and the
guidelines of the Indian Council of Medical Research for
bio-medical research involving human subjects [11]. Fur-
thermore, the study was approved by the Institutional Sci-
entific Advisory Committee and the Institutional Ethical
Committee. The study was "blind" to the extent that pa-
tients, clinicians evaluating the adverse effects, and labo-
ratory staff carrying out the laboratory tests and measuring
mf and antigen levels, were unaware of the individual
therapy schedules. Blinding and coding of the drugs was
done by an independent monitor (a senior scientist who
was not an investigator) after repacking in look-alike cap-
sules by a pharmaceutical company in Pondicherry. The
codes were broken only after completion of the study.
Assay of filarial antigenaemia
Qualitative detection of circulating filarial antigen was de-
termined by use of an immuno-chromatographic (ICT)
card test (ICT Diagnostics, St. Balgowlah, Australia) on 50
µl of serum collected on days 0, 3, 7, 30, 90, 180, 270 and
360.
Quantitative detection of circulating filarial antigen was
determined by use of an Og4C3 ELISA test kit (M/S Trop-
Figure 1
Overall incidence rate of adverse reactions in the three drug
groups over the first 96 hours post-therapy (Alb: albenda-
zole, DEC: diethylcarbamazine citrate, Alb + DEC: albenda-
zole + diethylcarbamazine citrate).
Figure 2
Fever incidence rate in the three drug groups over the first
96 hours post-therapy (Alb: albendazole, DEC: diethylcar-
bamazine citrate, Alb + DEC: albendazole + diethylcar-
bamazine citrate).Filaria Journal 2002, 1 http://www.filariajournal.com/content/1/1/1
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Bio, Australia) on 50 µl of serum collected on days 0, 7
and 360.
Data analyses
The relative tolerability of the three drug regimens was
compared using the incidence and intensity score of the
adverse reactions for a period of 4 days (96 hours) post-
therapy. The incidence of adverse reactions in each group
was calculated as the proportion of individuals complain-
ing of any reaction up to, and including, day 4 post-ther-
apy. The day-specific prevalence in each group was
calculated as the proportion of individuals complaining
of any reaction on the particular day of follow-up post-
therapy. The total and day-specific mean reaction intensi-
ty scores were also calculated. The relative efficacy of the
three drug regimens was compared using the clearance
and density of microfilaraemia and antigenaemia among
patients in the three drug groups. For this, the clearance
(the proportion of patients who became amicrofilaraemic
out of the total number of patients in a particular drug
group) and proportion change in the geometric mean mf
count in the three drug groups at different time points was
compared with the pre-therapy levels. The day specific
proportion positivity in the qualitative (ICT) and quanti-
tative (Og4C3) antigenaemia tests was also calculated.
Statistical analyses
The Chi-square test was used for comparing proportions
(incidence of adverse reaction, antigen positivity) be-
tween the three drug groups. For comparing means (ad-
verse reaction score), a non-parametric Mann-Whitney U-
test was used. Microfilarial counts were logarithmically
transformed and the Student's t-test was carried out for
comparison of mean counts of mf and mean optical den-
sity values of Og4C3 test results between the drug groups.
Correlation analysis was carried out to test any association
between mf count and adverse reaction score.
Results
The age and gender class distribution of the 54 patients in
the three drug groups is shown in Table 2. Pre-therapy mf
counts in patients ranged from 22 to 606 per mL of ve-
nous blood, and the geometric mean pre-therapy mf lev-
els between the three drug groups did not differ
significantly (Table 2).
Tolerability
The incidence of adverse reactions was 42.1% (albenda-
zole), 52.9% (DEC) and 61.1% (albendazole + DEC) (Ta-
ble 3). Fever, headache and myalgia were the
predominant adverse reactions in all three drug groups.
Adverse reactions in all the three drug groups were tran-
sient (not beyond 6 days) and only required symptomatic
treatment in some cases. No life-threatening adverse reac-
tions were observed in any of the patients. The incidence
of adverse reactions was independent of age and gender
(Table 4), and was highest on day 2 post-therapy in all
three drug groups (Figures 1,2,3,4). The mean score of ad-
verse reaction intensity (± SD) did not differ significantly
between the DEC and albendazole + DEC groups (5.6 ±
7.1 vs. 6.7 ± 6.6; Z = 1.5; P = 0.165). However, the mean
score for albendazole alone was significantly lower when
compared to the DEC and albendazole + DEC groups (1.8
± 3.0; Z = 2.1; P = < 0.05). The mean intensity of the three
Figure 3
Headache incidence rate in the three drug groups over the
first 96 hours post-therapy (Alb: albendazole, DEC: diethyl-
carbamazine citrate, Alb + DEC: albendazole + diethylcar-
bamazine citrate).
Figure 4
Myalgia incidence rate in the three drug groups over the first
96 hours post-therapy (Alb: albendazole, DEC: diethylcar-
bamazine citrate, Alb + DEC: albendazole + diethylcar-
bamazine citrate).Filaria Journal 2002, 1 http://www.filariajournal.com/content/1/1/1
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major specific adverse reactions (fever, headache and my-
algia) also peaked on day 2 post-therapy in all three drug
groups (Figures 5,6,7,8).
In the albendazole and the DEC groups, there was no sig-
nificant correlation between the pre-therapy microfilarial
count and adverse reaction scores [r = 0.10, t = 0.414; P =
0.684 (albendazole); r = 0.41, t = 1.76; P = 0.098 (DEC)].
There was however, a significant correlation between the
pre-therapy microfilarial counts and overall adverse reac-
tion scores in the albendazole + DEC group (r = 0.58, t =
2.81; P = 0.013) and between the three predominant ad-
verse reactions [r = 0.56, t = 2.73; P = 0.015 (fever score);
r = 0.62, t = 3.1; P = 0.006 (headache score); r = 0.51, t =
2.4; P = 0.029 (myalgia score)].
Haematological and biochemical parameters were within
normal limits and did not change significantly between
Figure 5
Overall mean score of adverse reactions in the three drug
groups over the first 96 hours post-therapy (Alb: albenda-
zole, DEC: diethylcarbamazine citrate, Alb + DEC: albenda-
zole + diethylcarbamazine citrate).
Figure 6
Mean reaction score of fever in the three drug groups over
the first 96 hours post-therapy (Alb: albendazole, DEC:
diethylcarbamazine citrate, Alb + DEC: albendazole +
diethylcarbamazine citrate).
Figure 7
Mean reaction score of headache in the three drug groups
over the first 96 hours post-therapy (Alb: albendazole, DEC:
diethylcarbamazine citrate, Alb + DEC: albendazole +
diethylcarbamazine citrate).
Figure 8
Mean reaction score of myalgia in the three drug groups over
the first 96 hours post-therapy (Alb: albendazole, DEC:
diethylcarbamazine citrate, Alb + DEC: albendazole +
diethylcarbamazine citrate).Filaria Journal 2002, 1 http://www.filariajournal.com/content/1/1/1
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day 0 (pre-therapy) and day 7 post-therapy in any of the
three drug groups (data not shown).
Efficacy
Clearance of mf
None of the patients in any of the drug groups showed
complete clearance of mf up to day 30 post-therapy. How-
ever, 5.3% of patients in the albendazole group became
amicrofilaraemic by day 90 post-therapy compared with
none in the DEC and albendazole + DEC drug groups. By
day 360 post-therapy, the proportion of patients who be-
came amicrofilaraemic was 26.3% (albendazole), 17.6%
(DEC) and 27.8% (albendazole + DEC), and there was no
significant difference between the drug groups (X2 = 0.58;
P = 0.748) (Figure 9).
Pattern of change in parasite density
The geometric mean density of microfilaraemia on differ-
ent days post-therapy was expressed as a percentage of the
pre-therapy geometric mean in each drug group. On day 3
post-therapy, the geometric mean density was 91.3% (al-
bendazole), 73.8% (DEC) and 64.3% (albendazole +
DEC) of the pre-therapy levels. By day 7 post-therapy,
these values had decreased to 85.9%, 63.3% and 54.9%
respectively. Considerable reduction in the density of mf
was observed by day 90 and 180 post-therapy with the
values (% pre-therapy) ranging from 19.0% to 34.9% in
the different groups. By day 360 post-therapy, these values
were 5.3% (albendazole), 10.4% (DEC) and 4.6% (alben-
dazole) accounting for a significant reduction of 94.7%,
89.6% and 95.4% respectively (P < 0.05) (Figure 10). Al-
Table 3: Incidence and mean score of different adverse reactions in the three drug groups
Adverse reactions Alb (n = 19) DEC (n = 17) Alb + DEC (n = 18)
Incidence %* Mean score Incidence %* Mean score Incidence %* Mean score
Fever 31.6 0.9 40.1 2.6 55.6 2.8
Chills 0.0 0.0 5.9 0.1 0.0 0.0
Cough 0.0 0.0 5.9 0.1 0.0 0.0
Headache 5.3 0.1 35.3 1.2 44.4 1.3
Giddiness 0.0 0.0 5.9 0.1 0.0 0.0
Myalgia 21.0 0.5 29.4 1.4 50.0 1.8
Arthralgia 0.0 0.0 0.0 0.0 5.6 0.1
Diarrhoea 0.0 0.0 0.0 0.0 0.0 0.0
Nausea 0.0 0.0 5.9 0.2 5.6 0.1
Vomiting 0.0 0.0 0.0 0.0 5.6 0.1
Abdominal pain 0.0 0.0 0.0 0.0 5.6 0.1
Chest pain 0.0 0.0 0.0 0.0 0.0 0.0
Overall 42.1 1.8 52.9 5.6 61.1 6.7
* = % of "n" in each group Alb = albendazole, DEC = diethylcarbamazine citrate, Alb + DEC = albendazole + diethylcarbamazine citrate
Table 4: Age and gender specific adverse reaction incidence (%) and mean intensity of score in the three drug groups.
No. of cases (n = 54) Adverse Reaction Incidence (%) Adverse Reaction Intensity score (mean ± 
SD)
Alb DEC Alb + DEC Alb DEC Alb + DEC Alb DEC Alb + DEC
≤  14 years 9 7 8 33.3 57.1 75.0 1.0 (± 1.7) 5.1 (± 5.1) 7.5 (± 5.7)
> 14 years 10 10 10 50.5 50.0 50.0 2.5 (± 3.8) 5.9 (± 8.5) 6.1 (± 7.4)
Male 10 8 9 50.0 62.5 55.6 2.4 (± 3.8) 7.4 (± 8.9) 5.8 (± 6.1)
Female 9 9 9 33.3 44.4 66.7 1.1 (± 1.8) 4.0 (± 5.0) 7.7 (± 7.2)
Alb = albendazole, DEC = diethylcarbamazine citrate, Alb + DEC = albendazole + diethylcarbamazine citrateFilaria Journal 2002, 1 http://www.filariajournal.com/content/1/1/1
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though the geometric mean mf count for the albendazole
+ DEC group was relatively lower at all time points post-
therapy (particularly marked in the early post-therapy pe-
riod), it did not vary significantly between the three drug
groups at any time point (P > 0.05).
Pattern of change in frequency distribution of parasite density
The relative changes in the frequency distribution of pa-
tients with different mf counts on day 0 (pre-therapy) and
day 180 and 360 post-therapy in the three drug groups are
shown in Figures 11,12,13. The pattern of change shows a
shift of high-count individuals to low or zero count (mov-
ing from right-sided tail of the distribution to left) over
time which is similar in all three drug groups. There was
no significant difference (P > 0.05) in the mean mf counts
either between gender or age classes at either day 0 or at
day 360 post-therapy in the three drug groups.
Antigenaemia clearance by ICT
The prevalence of filarial antigenaemia in the different
drug groups showed a gradual declining trend (Figure 14).
Figure 9
Comparison of the pattern of mf positivity in the three drug
groups on different days post-therapy (Alb: albendazole,
DEC: diethylcarbamazine citrate, Alb + DEC: albendazole +
diethylcarbamazine citrate).
Figure 10
Percentage change in the geometric mean mf density in the
three drug groups compared to pre-therapy level at different
days post-therapy (Alb: albendazole, DEC: diethylcar-
bamazine citrate, Alb + DEC: albendazole + diethylcar-
bamazine citrate).
Figure 11
Pattern of distribution of microfilaraemic patients according
to pre-therapy mf counts in the three drug groups (Alb:
albendazole, DEC: diethylcarbamazine citrate, Alb + DEC:
albendazole + diethylcarbamazine citrate).Filaria Journal 2002, 1 http://www.filariajournal.com/content/1/1/1
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The percentage reduction in the filarial antigen prevalence
was 83% (albendazole), 87% (DEC) and 75% (albenda-
zole + DEC) by day 360 post-therapy. Logistic regression
analysis showed that antigen positivity was independent
of the drug group during the period of observation (Wald
statistics: 0.615; P = 0.735). The prevalence of antigenae-
mia did not differ significantly between the drug groups at
any time point during the study (P > 0.05).
Antigenaemia clearance by Og4C3 assay
Filarial antigenaemia prevalence as measured by Og4C3
assay showed a similar pattern to that of the ICT test prev-
alence by day 360 post-therapy. Og4C3 mean optical den-
sity (± SD) in all three drug groups was significantly
reduced from day 0 (pre-therapy) levels by day 360 post-
therapy [0.49 ± 0.16 vs. 0.08 ± 0.17, t = 7.62; P = < 0.0001
(albendazole); 0.39 ± 0.21 vs. 0.07 ± 0.15, t = 5.36; P = <
0.0001 (DEC); 0.47 ± 0.18 vs. 0.07 ± 0.15, t = 9.98; P = <
0.0001 (albendazole + DEC)] accounting for a percentage
reduction in the filarial antigenaemia prevalence of 83%
(albendazole), 80% (DEC) and 81% (albendazole +
DEC) (Table 5).
Discussion
This is the first report of a hospital-based clinical study on
the comparative tolerability and efficacy of either a single
dose of albendazole or its co-administration with DEC in
Wuchereria bancrofti microfilaraemic patients in India. The
study has clearly shown that single dose regimens of either
albendazole, DEC or albendazole + DEC are well tolerat-
ed and efficacious. Although no individual patient in any
of the drug groups showed complete clearance of micro-
filaraemia (i.e. became amicrofilaremic) by day 30 post-
therapy (Figure 9), the pattern of decline in mean micro-
filaria density (Figure 10) in the first seven days post-ther-
apy revealed that either DEC alone or when co-
administered with albendazole resulted in a relatively rap-
id decline when compared to albendazole alone. The fast-
er decline of mean microfilaria density in the DEC and
albendazole + DEC groups also correlated with the higher
mean score of adverse reaction intensity as compared to
albendazole alone. The delayed reduction in mf density
due to albendazole alone suggests a different mode of ac-
tion of this drug, either by damage or sterilization of the
adult worm. The difference in the pattern of change in mf
density in the first week post-therapy between the three
drug groups could explain the difference in the adverse re-
actions incidence rate. For example in the albendazole
group the change in mf density was minimal as also the
adverse reaction incidence. The decline in prevalence of
antigenaemia was relatively gradual compared to the de-
cline in microfilaraemia prevalence by day 360 post-ther-
apy (about one year) in all three drug groups.
Figure 12
Pattern of distribution of microfilaraemic patients according
to mf counts in the three drug groups on day 180 post-ther-
apy (Alb: albendazole, DEC: diethylcarbamazine citrate, Alb +
DEC: albendazole + diethylcarbamazine citrate).
Figure 13
Pattern of distribution of microfilaraemic patients according
to mf counts in the three drug groups on day 360 post-ther-
apy (Alb: albendazole, DEC: diethylcarbamazine citrate, Alb +
DEC: albendazole + diethylcarbamazine citrate).
Figure 14
Antigenaemia positivity rate by ICT in the three drug groups
on different days post-therapy (Alb: albendazole, DEC:
diethylcarbamazine citrate, Alb + DEC: albendazole +
diethylcarbamazine citrate).Filaria Journal 2002, 1 http://www.filariajournal.com/content/1/1/1
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Comparison of the results of the current study, (particu-
larly with regard to efficacy of albendazole alone or when
co-administered with DEC), with previously published
data [12–15] revealed that there is a broad agreement in
the trend of decline in microfilaria prevalence and density
across the studies (although the time points of follow-up
and dosage of albendazole were different). However, this
study demonstrated the highest level of decline in mf
prevalence compared to pre-therapy values, after a one-
year follow-up, than similar previous studies (Table 6).
Annual mass administration of single dose anti-filarial
drugs to entire endemic communities for the control of
transmission of lymphatic filariasis is currently the recom-
mended strategy for the Global Alliance for the Elimina-
tion of Lymphatic Filariasis (GAELF) [1,3–6]. The World
Health Organization (WHO) has set the target for global
elimination of lymphatic filariasis by the year 2020 [1]
and India, which has roughly 40% of the global burden,
has set its target for national elimination by the year 2015
[16]. The realization of these goals will largely depend on
the use of safe, tolerable and efficacious single dose drug
regimens, which will not only improve community ac-
ceptance, compliance and coverage of mass drug adminis-
trations, but also decrease costs by simplifying drug
distribution.
The results of the current and previous studies [12–
15],[17,18] strengthen the rationale of including albenda-
zole with either DEC or ivermectin for mass annual single
dose administration by the GAELF (particularly for
Wuchereria bancrofti, which accounts for over 90% of the
global burden of lymphatic filariasis). Of all the anti-filar-
ial drugs, single dose albendazole (400 mg) is safest, as it
produces the least adverse reactions in microfilaria carri-
ers. Therefore, it is expected to be widely accepted by the
population in endemic communities, even when the prev-
alence of infection and parasite density is high [19]. Fur-
thermore, albendazole (unlike DEC) is safe for mass
administration in countries and regions where lymphatic
filariasis is co-endemic with onchocerciasis and/or loiasis
[18]. The efficacy of single dose albendazole (400 mg) in
terms of reduction in microfilaria density at the end of
one year (particularly considering its use in endemic com-
munities in cycles of one year) is equal to DEC alone or
it's co-administration with DEC.
As well as being safe, tolerable and efficacious, albenda-
zole has significant "beyond filariasis" benefits when
compared to other anti-filarial drugs [18]. It has a broad-
spectrum effect on intestinal helminths (and some proto-
zoan parasites) and, consequently, improves nutritional
status and cognitive functions, particularly in children.
This will be of particular importance in countries, such as
India, where specific nutrition supplementation pro-
grammes are being implemented by the national govern-
ment [20], and where the benefit of such programmes is
expected to be low because of the high prevalence of intes-
tinal parasites in the population [20,21]. Furthermore,
GlaxoSmithKline has generously committed itself to the
donation of albendazole to all countries endemic for lym-
phatic filariasis for as long as it is needed [1]. Therefore, as
far as albendazole is concerned, the cost or affordability to
an endemic country's national programme is not impor-
tant.
WHO currently recommends mass annual single dose co-
administration of albendazole with DEC (in countries
where onchocerciasis or loiasis is not co-endemic) or with
ivermectin (in countries where onchocerciasis or loiasis is
co-endemic) [1]. This recommendation is based on the
findings of previous hospital-based clinical trials [1,18].
Furthermore, a recent community-based trial in India,
showed that co-administration of two anti-filarial drugs,
(particularly DEC and ivermectin), could result in a rapid
and sustained reduction in parasite density, when com-
pared to administration of the drugs individually [22]. In
other communicable diseases such as leprosy and tuber-
Table 5: Day specific prevalence and intensity of Og4C3 in the three drug groups.
Day Prevalence (%) Mean Intensity of OD valuesa
Alb DEC Alb + DEC Alb DEC Alb + DEC
0 (pre-
therapy)
94.7 88.2 94.1 0.49 (± 0.16) 0.39 (± 0.21) 0.47 (± 0.18)
79 4 . 7 † 87.5† 88.2† 0.47† (± 0.19) 0.40† (± 0.22) 0.44† (± 0.25)
360 15.8** 17.6** 17.6** 0.08** (± 0.17) 0.07** (± 0.15) 0.08** (± 0.15)
a Data are mean ± SD. †P = non significant vs. day 0 (pre-therapy) **P = < 0.01 vs. day 0 (pre-therapy) Alb = albendazole, DEC = diethylcar-
bamazine citrate, Alb + DEC = albendazole + diethylcarbamazine citrateFilaria Journal 2002, 1 http://www.filariajournal.com/content/1/1/1
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culosis, multi-drug regimens are used for the treatment of
individual patients with a view of preventing drug resist-
ance [23,24]. Unlike the mycobacterium pathogens which
cause leprosy and tuberculosis, there are no reports of
lymphatic filarial parasites developing resistance to anti-
filarial drugs. DEC, in particular, has been in use for al-
most five decades without any evidence of development
of resistance [3]. Although variability in the sensitivity to
albendazole by intestinal parasites from different regions
of the world has been reported [25], a recent study using
a genetic marker, (for the β -tubulin gene), has shown that
strains of Wuchereria bancrofti from different parts of India
are sensitive to benzimidazole compounds [26]. Howev-
er, in view of the fact that mass annual single dose drug
administration will have to be carried out for a number of
annual cycles (for a decade or more if necessary) and that
the three key drugs for the control of lymphatic filariasis,
namely, albendazole, DEC and ivermectin are known to
have different mechanisms of action on lymphatic filarial
parasites [17], it may be prudent to co-administer two
drugs (albendazole with DEC or ivermectin [depending
on whether the region is co-endemic for onchocerciasis
and/or loiasis]), so that the possibility of selection of filar-
ial parasites with lowered sensitivity to any one single
anti-filarial drug is prevented [1].
In spite of this generalization, it should be understood
that the choice of drug for a particular region could de-
pend on other local factors such as degree of endemicity.
For example, in areas with high endemicity and high
mean parasite density, albendazole alone could be the
drug of choice for the first few rounds of MDA, (before co-
administration with another anti-filarial drug is imple-
mented), as community acceptance and compliance will
be high due to the lower adverse reactions seen with al-
bendazole.
The current study was carried out using relatively small
numbers of asymptomatic Wuchereria bancrofti microfila-
raemic volunteers from South India. Therefore, the results
of this study should not be generalized for all endemic ar-
eas. Further data needs to be generated from both multi-
centre hospital- and community-based studies in different
settings within India and other endemic countries, to
build further the evidence base for achieving the goal of
global elimination of lymphatic filariasis.
Table 6: Comparison of the efficacy of albendazole alone or with DEC in the current study with data published previously.
Trials Follow-up time (days post-therapy)
0 7 30 90 120 180 270 360 15 m*
A) Prevalence (% of cases)
Current study
Alb 400 mg 100.0 100.0 100.0 94.7 - 94.7 84.2 73.7 -
Alb 400 mg + DEC 6 mg/kg bodyweight 100.0 100.0 100.0 100.0 - 94.4 83.3 72.2 -
Previous studies (single dose) Alb 400 mg
Ismail et al., ( 1 9 9 8 ) † -------- 9 1 . 7
Addiss et al., (1997) - - - - 76.0 - - - -
Beach et al., ( 1 9 9 9 ) ---- 8 5 . 0 ----
Dunyo et al. ,  ( 2 0 0 0 ) ------- 9 1 . 9 -
Previous studies (single dose) Alb 400 mg + DEC 6 mg/kg
Ismail et al., ( 1 9 9 8 ) † -------- 7 2 . 7
B) Changes in parasite density (geometric mean) as compared to pre-therapy level
Current study
Alb 400 mg 100.0 85.9 59.5 34.9 - 25.8 14.5 5.3 -
Alb 400 mg + DEC 6 mg/kg bodyweight 100.0 54.9 39.1 22.0 - 19.0 12.3 4.6 -
Previous studies (single dose) Alb 400 mg
Ismail et al., ( 1 9 9 8 ) † -------- 9 . 8
Addiss et al., (1997) - - - - 63.8 - - - -
Beach et al. ,  ( 1 9 9 9 ) ---------
Dunyo et al., (2000) - ------ 3 1 . 7 -
Previous studies (single dose) Alb 400 mg + DEC 6 mg/kg
Ismail et al., ( 1 9 9 8 ) † -------- 1 . 3
-Data not available †albendazole 600 mg *15 months post-therapy Alb = albendazole, DEC = diethylcarbamazine citrateFilaria Journal 2002, 1 http://www.filariajournal.com/content/1/1/1
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Note
In the case of children who were ≤  12 years old, written in-
formed consent was given by their parents. All children
who where > 12 years gave written informed consent for
themselves and their parents were also fully informed and
agreed to the participation of the child in the study.
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